An open assessment of the efficacy and tolerability of diclofenac sodium (Voltarol) in patients with rheumatic disease and a comparative study of diclofenac sodium (Voltarol) with indomethacin in patients with osteoarthritis and rheumatoid arthritis. 1979

M F McMahon, and H C Cash

The efficacy and tolerability of diclofenac was studied in an initial two-week assessment study in 24 patients with rheumatic disease. During the first week patients received 1 x 25 mg diclofenac t.d.s., with subsequent dosage adjustments according to response. Most completers showed improvement in joint pain and functional grade, and patients' rating of their condition indicated a significant improvement. Nine patients were withdrawn because of poor symptom control or side-effects, and there were a number of other minor side-effects not necessitating withdrawal. However, there were no persistent or lasting side-effects, and laboratory tests revealed no significant abnormalities. In a two-week double-blind study, diclofenac was compared with indomethacin in 43 outpatients with osteoarthritis or rheumatoid arthritis. Dosage in the first week was 1 x 25 mg tablet of either diclofenac or indomethacin (random allocation) t.d.s., with further adjustments as necessary. There were no significant differences in the effectiveness of the two drugs, and no differences in dosage requirements. Three patients were withdrawn from each treatment group. Gastrointestinal side-effects predominated in the diclofenac-treated group, with central nervous system unwanted effects more frequent in the indomethacin group.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010003 Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans. Arthritis, Degenerative,Osteoarthrosis,Osteoarthrosis Deformans,Arthroses,Arthrosis,Arthritides, Degenerative,Degenerative Arthritides,Degenerative Arthritis,Osteoarthritides,Osteoarthroses
D010648 Phenylacetates Derivatives of phenylacetic acid. Included under this heading are a variety of acid forms, salts, esters, and amides that contain the benzeneacetic acid structure. Note that this class of compounds should not be confused with derivatives of phenyl acetate, which contain the PHENOL ester of ACETIC ACID. Benzeneacetates,Benzeneacetic Acids,Phenylacetic Acids,Acids, Benzeneacetic,Acids, Phenylacetic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004008 Diclofenac A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. Diclophenac,Dichlofenal,Diclofenac Potassium,Diclofenac Sodium,Diclonate P,Dicrofenac,Feloran,GP-45,840,Novapirina,Orthofen,Orthophen,Ortofen,SR-38,Sodium Diclofenac,Voltaren,Voltarol,Diclofenac, Sodium,GP 45,840,GP45,840,SR 38,SR38
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females

Related Publications

M F McMahon, and H C Cash
January 1978, Scandinavian journal of rheumatology. Supplement,
M F McMahon, and H C Cash
November 1979, International journal of clinical pharmacology and biopharmacy,
M F McMahon, and H C Cash
November 1985, Seminars in arthritis and rheumatism,
M F McMahon, and H C Cash
May 1978, Rheumatology and rehabilitation,
M F McMahon, and H C Cash
January 1979, Rheumatology and rehabilitation,
Copied contents to your clipboard!